Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Unicet Biotech Co. LLC is currently prosecuting 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter constitutes the entire active workload for the company at the USPTO. The focus on 1 pending office action suggests a highly targeted approach to securing intellectual property, where all current legal resources are dedicated to a specific application.
The examination is being handled by 1 distinct examiner, DACE DENITO, ALEXANDRA GERALDINE. As the only official assigned to the portfolio, DACE DENITO, ALEXANDRA GERALDINE is also the busiest examiner with 1 pending office action under her review. This prosecution is taking place within 1 distinct art unit, which further emphasizes the concentrated nature of the company's current patent activities in the Biotechnology & Pharmaceuticals field.
For a practitioner, the presence of 1 distinct examiner and 1 distinct art unit for the 1 pending office action simplifies the interaction with the USPTO. There is no requirement to manage different examiner styles or art unit interpretations, as all activity is localized. This portfolio benefits from a direct line of communication with DACE DENITO, ALEXANDRA GERALDINE, ensuring a consistent prosecution path for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285847 | METHODS TO IMPROVE STABILITY OF VIRUS TRANSDUCTION OF y8 T CELLS AND APPLICATIONS THEREOF | DACE DENITO, ALEXANDRA GERALDINE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285847 | METHODS TO IMPROVE STABILITY OF VIRUS TRANSDUCTION OF y8 T CELLS AND APPLICATIONS THEREOF | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | Oct 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUnicet Biotech Co. LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexandra Geraldine Dace Denito has the most, with 1 of Unicet Biotech Co. LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
